Opinion of the Transparency Council – cetuximab B.52
At its meeting on 26 August 2024, the Transparency Council adopted opinion No. 134/2024 on the transfer of the active substance cetuximab from the drug program: B.52 “Treatment of squamous cell carcinoma of the organs of the head and neck” to the catalog of reimbursable drugs in chemotherapy.